Search - tctmd.com

Displaying 61 - 80 of 100

Sort: Relevancy | Date

Presentation The Structural Heart Disease Summit 2018

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Presenter: Susheel K. Kodali, Michael J. Reardon, Patrick M. McCarthy

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Presenter: Susheel K. Kodali, Michael J. Reardon, Mathew Williams

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Presenter: Allan Schwartz, Stephan Windecker, Michael J. Reardon

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Case #3: A Small (Undersized) Surgical Bioprosthesis

Presenter: Michael J. Reardon, Adnan K. Chhatriwalla, Danny Dvir, Ariel Finkelstein, Kendra J. Grubb, Michael J. Mack, Thomas Modine, Mark J. Russo

June 21, 2018

News Conference News SCAI 2018

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

Shelley Wood

April 28, 2018

News Daily News

New Surgical Valve Durability Data Set ‘Critical Benchmark’ for TAVR Devices

Yael L. Maxwell

March 26, 2018

News Conference News TCT 2017

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Yael L. Maxwell

November 09, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Presentation TCT 2017

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

Presenter: Michael J. Reardon, Didier Tchetche, Alexandra J. Lansky

October 31, 2017

Presentation TCT 2017

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Presenter: Michael J. Reardon

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

News Daily News

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Caitlin E. Cox

September 29, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

Presentation SWVS 2017

Cases: The Good, The Bad and The Ugly

Presenter: Michael J. Reardon

May 07, 2017

Presentation SWVS 2017

Extreme Sizing: The Very Small and the Very Large

Presenter: Michael J. Reardon

May 06, 2017

Presentation SWVS 2017

TAVR: Evolving Risk Assessment and Expectations

Presenter: Michael J. Reardon

May 06, 2017

Presentation SWVS 2017

Heart Valve Dysfunction With ESRD: Options and Expectations

Presenter: Michael J. Reardon

May 06, 2017

Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: First Results from the SURTAVI Clinical Trial

Presentation ACC 2017

First Results from the SURTAVI Clinical Trial

Presenter: Michael J. Reardon

March 17, 2017

News Conference News ACC 2017

Live From Washington: ACC 2017, Day One

Shelley Wood

March 17, 2017

News Conference News ACC 2017

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Todd Neale

March 17, 2017

Advertisement

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Point: TAVR Will Be the Treatment of Choice for Bicuspid Aortic Valve Disease in the Future!

Once the Cycle of Low-Risk Studies is Completed, Predicting the Role of Surgery and Surgeons in the Treatment of Aortic Stenosis

Case #3: A Small (Undersized) Surgical Bioprosthesis

Debate Over Cerebral Protection in TAVR Fizzles in the Face of Reimbursement Hopes

New Surgical Valve Durability Data Set ‘Critical Benchmark’ for TAVR Devices

Selection Bias? Debate Asks How Many TAVR Devices Centers Should Stock

Point A Multi-Device Lesion-Specific Approach is Preferred!

The Compelling Saga of Stroke after TAVR: Key Messages From NeuroARC

LOTUS TAVR Technology Review (Including EDGE) and Clinical Program Updates

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Cases: The Good, The Bad and The Ugly

Extreme Sizing: The Very Small and the Very Large

TAVR: Evolving Risk Assessment and Expectations

Heart Valve Dysfunction With ESRD: Options and Expectations

First Results from the SURTAVI Clinical Trial

Live From Washington: ACC 2017, Day One

SURTAVI Lends More Support to Use of TAVR in Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content